174 related articles for article (PubMed ID: 21245938)
1. Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer.
McCabe NP; Kerr BA; Madajka M; Vasanji A; Byzova TV
Neoplasia; 2011 Jan; 13(1):31-9. PubMed ID: 21245938
[TBL] [Abstract][Full Text] [Related]
2. Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition.
McCabe NP; Madajka M; Vasanji A; Byzova TV
Clin Exp Metastasis; 2008; 25(5):581-90. PubMed ID: 18506587
[TBL] [Abstract][Full Text] [Related]
3. Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone.
Sharma S; Xing F; Liu Y; Wu K; Said N; Pochampally R; Shiozawa Y; Lin HK; Balaji KC; Watabe K
J Biol Chem; 2016 Sep; 291(37):19351-63. PubMed ID: 27422817
[TBL] [Abstract][Full Text] [Related]
4. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
5. Review of cellular mechanisms of tumor osteolysis.
Clohisy DR; Perkins SL; Ramnaraine ML
Clin Orthop Relat Res; 2000 Apr; (373):104-14. PubMed ID: 10810467
[TBL] [Abstract][Full Text] [Related]
6. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathway for cancer metastasis to bone.
De S; Chen J; Narizhneva NV; Heston W; Brainard J; Sage EH; Byzova TV
J Biol Chem; 2003 Oct; 278(40):39044-50. PubMed ID: 12885781
[TBL] [Abstract][Full Text] [Related]
8. The role of osteoclastic activity in prostate cancer skeletal metastases.
Keller ET
Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
[TBL] [Abstract][Full Text] [Related]
9. Micro-CT combined with bioluminescence imaging: a dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model.
Fritz V; Louis-Plence P; Apparailly F; Noël D; Voide R; Pillon A; Nicolas JC; Müller R; Jorgensen C
Bone; 2007 Apr; 40(4):1032-40. PubMed ID: 17251073
[TBL] [Abstract][Full Text] [Related]
10. Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer.
Hardaway AL; Herroon MK; Rajagurubandara E; Podgorski I
Clin Exp Metastasis; 2015 Apr; 32(4):353-68. PubMed ID: 25802102
[TBL] [Abstract][Full Text] [Related]
11. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
[TBL] [Abstract][Full Text] [Related]
12. Notch activation promotes bone metastasis via SPARC inhibition in adenoid cystic carcinoma.
Zhang Y; Liu X; Zhu L; Zhou Z; Cui Y; Zhou CX; Li TJ
Oral Dis; 2024 Apr; 30(3):1220-1233. PubMed ID: 36951790
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.
Podgorski I; Linebaugh BE; Koblinski JE; Rudy DL; Herroon MK; Olive MB; Sloane BF
Am J Pathol; 2009 Sep; 175(3):1255-69. PubMed ID: 19700761
[TBL] [Abstract][Full Text] [Related]
14. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
15. p62/sequestosome 1 deficiency accelerates osteoclastogenesis
Zach F; Polzer F; Mueller A; Gessner A
J Biol Chem; 2018 Jun; 293(24):9530-9541. PubMed ID: 29555685
[TBL] [Abstract][Full Text] [Related]
16. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
Liu J; Li D; Dang L; Liang C; Guo B; Lu C; He X; Cheung HY; He B; Liu B; Li F; Lu J; Wang L; Shaikh AB; Jiang F; Lu C; Peng S; Zhang Z; Zhang BT; Pan X; Xiao L; Lu A; Zhang G
Sci Rep; 2017 Jan; 7():40487. PubMed ID: 28071724
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.
Bendre MS; Montague DC; Peery T; Akel NS; Gaddy D; Suva LJ
Bone; 2003 Jul; 33(1):28-37. PubMed ID: 12919697
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
